Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide
(2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on
lung function in patients with Cystic Fibrosis. The selection of the optimal dose will be
based on bronchodilator efficacy, safety evaluations and pharmacokinetic evaluations